Skip to main content
OpenTrials

Clinical trial condition

Bronchial Neoplasms

Explore clinical trials studying Bronchial Neoplasms. Study availability and eligibility vary by location and protocol.

5,282 public trials 1,196 recruiting studies
Refine in advanced search Browse all conditions

Bronchial Neoplasms trial results

Completed

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

NCT03307785

Conditions
Advanced Cancer, Bronchial Neoplasms, Carcinoma, Bronchogenic, +17 more
Locations
  • GSK Investigational Site Scottsdale, Arizona, United States
  • GSK Investigational Site Encinitas, California, United States
  • GSK Investigational Site San Marcos, California, United States
  • GSK Investigational Site Sarasota, Florida, United States
View Trial Details
Completed

Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

NCT04644237

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • University of Colorado Denver - Anschutz Medical Campus Aurora, Colorado, United States
  • AdventHealth Orlando Orlando, Florida, United States
  • H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida, United States
  • Norton Cancer Institute Louisville, Kentucky, United States
View all 50 locations
View Trial Details
Completed

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

NCT02157883

Conditions
Advanced (Inoperable) Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Bronchial Neoplasms, +9 more
Locations
  • Research Site San Diego, California, United States
  • Research Site Cleveland, Ohio, United States
  • Research Site Edegem, Belgium
  • Research Site Ghent, Belgium
View all 16 locations
View Trial Details
Completed

Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

NCT01186861

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Site US10007 Jacksonville, Florida, United States
  • Site US10001 Port Saint Lucie, Florida, United States
  • Site US10002 Albany, Georgia, United States
  • Site US10008 Chicago, Illinois, United States
View all 69 locations
View Trial Details
Completed

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

NCT01221077

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • University of California, San Diego/Moores Cancer Center La Jolla, California, United States
  • H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
  • Cleveland Clinic Florida Weston, Florida, United States
  • Northwestern Memorial Hospital Chicago, Illinois, United States
View all 29 locations
View Trial Details
Completed

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

NCT05954871

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +18 more
Locations
  • SCRI Oncology Partners Nashville, Tennessee, United States
  • START South Texas Accelerated Research Therapeutics-San Antonio San Antonio, Texas, United States
  • Border Medical Oncology Wodonga, New South Wales, Australia
  • St Vincent's Hospital Melbourne Fitzroy, Victoria, Australia
View Trial Details

Related conditions